Piper Sandler lowered the firm’s price target on Teladoc (TDOC) to $12 from $13 and keeps an Overweight rating on the shares following quarterly results. The firm considers 2025 a transition year for Integrated Care as client priorities change and contract terms evolve. Teladoc is “rightly focusing” on pricing and engagement, which Piper believes are the levers that can revive durable mid-single digits revenue growth in the Integrated Care segment.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TDOC:
- Teladoc’s Mixed Outlook: Hold Rating Amidst Growth Challenges and Uncertain Acquisitions
- Teladoc’s Mixed Performance and Strategic Challenges Lead to Hold Rating
- Teladoc Health Reports 2024 Earnings and Strategic Outlook
- Closing Bell Movers: Snowflake up 11%, Nvidia little changed after earnings
- TDOC Earnings: Teladoc Health Stock Falls 10% on Loss and Weak Outlook